Skip to main content
SpringerLink
Log in

Lymphome à cellules du manteau

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 552 Accesses

Résumé

Le lymphome à cellules du manteau (LCM) est un lymphome malin non hodgkinien (LMNH) de phénotype B dérivant d’une cellule naïve pré-centre germinatif. La présence d’une translocation entre les chromosomes 11 et 14 (t(11;14)) est la caractéristique cytogénétique de cette hémopathie mais elle n’en est pas spécifique [1]. Progressivement individualisé des autres LMNH dans les années 1990, le LCM correspond à une entité particulière au plan cytologique, phénotypique et génétique, dont les caractéristiques sont précisées dans la dernière version de la classification de l’OMS. La prise en charge thérapeutique de cette hémopathie maligne, considérée comme agressive, a progressivement évolué ces dernières années pour se distinguer des autres LMNH, d’oú l’importance de poser le bon diagnostic. Ces évolutions nosologiques puis thérapeutiques sont allées de pair avec une progression des connaissances touchant l’ontogenèse, l’oncogenèse et toute la biologie de ce lymphome. Malgré de grands progrès, le LCM demeure une pathologie considérée comme incurable, des progrès thérapeutiques sont donc encore nécessaires.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Swerdlow S, Campo E, Harris N, et al. (2008) Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, WHO

    Google Scholar 

  2. Zhou Y, Wang H, Fang W, et al. (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113: 791–8

    Article  PubMed  Google Scholar 

  3. Groves FD, Linet MS, Travis LB, et al. (2000) Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92: 1240–51

    Article  PubMed  CAS  Google Scholar 

  4. Jares P, Colomer D, Campo E (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7: 750–62

    Article  PubMed  CAS  Google Scholar 

  5. Navarro A, Royo C, Hernandez L, et al. (2011) Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. Semin Hematol 48: 155–65

    Article  PubMed  CAS  Google Scholar 

  6. Perez-Galan P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26–38

    Article  PubMed  CAS  Google Scholar 

  7. Navarro A, Bea S, Fernandez V, et al. (2009) MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res 69: 7071–8

    Article  PubMed  CAS  Google Scholar 

  8. Orchard J, Garand R, Davis Z, et al. (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, non-nodal disease. Blood 101: 4975–81

    Article  PubMed  CAS  Google Scholar 

  9. Pileri SA, Falini B (2009) Mantle cell lymphoma. Haematologica 94: 1488–92

    Article  PubMed  CAS  Google Scholar 

  10. Sander B (2011) Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol 28: 245–55

    Article  PubMed  Google Scholar 

  11. Carvajal-Cuenca A, Sua LF, Silva NM, et al. (2012) In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97: 270–8

    Article  PubMed  Google Scholar 

  12. Tiemann M, Schrader C, Klapper W, et al. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131: 29–38

    Article  PubMed  Google Scholar 

  13. Kelemen K, Peterson LC, Helenowski I, et al. (2008) CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23-disease. Am J Clin Pathol 130: 166–77

    Article  PubMed  Google Scholar 

  14. Chen YH, Gao J, Fan G, et al. (2010) Nuclear expression of SOX11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 23: 105–12

    Article  PubMed  CAS  Google Scholar 

  15. Mozos A, Royo C, Hartmann E, et al. (2009) SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94: 1555–62

    Article  PubMed  CAS  Google Scholar 

  16. Zeng W, Fu K, Quintanilla-Fend L, et al. (2012) Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol 36: 214–9

    Article  PubMed  Google Scholar 

  17. Fernandez V, Salamero O, Espinet B, et al. (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70: 1408–18

    Article  PubMed  CAS  Google Scholar 

  18. Ondrejka SL, Lai R, Kumar N, et al. (?) Indolent mantle cell leukemia: clinicopathologic variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96: 1121–7

    Google Scholar 

  19. Shakir R, Ngo N, Naresh KN (2008) Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 61: 920–7

    Article  PubMed  CAS  Google Scholar 

  20. Hao S, Sanger W, Onciu M, et al. (2002) Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol 15: 1266–72

    Article  PubMed  Google Scholar 

  21. Klapper W, Hoster E, Determann O, et al. (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop

    Google Scholar 

  22. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. (2010) Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 21: 133–9

    Article  PubMed  CAS  Google Scholar 

  23. Fu K, Weisenburger DD, Greiner TC, et al. (2005) Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 106: 4315–21

    Article  PubMed  CAS  Google Scholar 

  24. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. (2008) Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111: 5683–90

    Article  PubMed  CAS  Google Scholar 

  25. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, et al. (2009) Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 94: 1595–8

    Article  PubMed  CAS  Google Scholar 

  26. Andersen NS, Jensen MK, de Nully Brown P, et al. (2002) A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 38: 401–8

    Article  PubMed  CAS  Google Scholar 

  27. Le Gouill S (2010) [Mantle cell lymphoma: an overview from diagnosis to future therapies]. Rev Med Interne 31: 615–20

    Article  PubMed  Google Scholar 

  28. Hoster E, Dreyling M, Klapper W, et al. (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111: 558–65

    Article  PubMed  CAS  Google Scholar 

  29. Bodet-Milin C, Touzeau C, Leux C, et al. (2010) Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 37: 1633–42

    Article  PubMed  CAS  Google Scholar 

  30. Vela-Chavez T, Adam P, Kremer M, et al. (2011) Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leuk Lymphoma 52: 458–66

    Article  PubMed  CAS  Google Scholar 

  31. Dreyling M, Weigert O, Hiddemann W (2008) Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol 19(Suppl 4): iv41–4

    Article  PubMed  Google Scholar 

  32. Ghielmini M, Zucca E (2009) How I treat mantle cell lymphoma. Blood 114: 1469–76

    Article  PubMed  CAS  Google Scholar 

  33. Herrmann A, Hoster E, Zwingers T, et al. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27: 511–8

    Article  PubMed  Google Scholar 

  34. Schulz H, Bohlius JF, Trelle S, et al. (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99: 706–14

    Article  PubMed  CAS  Google Scholar 

  35. Lenz G, Dreyling M, Hoster E, et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984–92

    Article  PubMed  CAS  Google Scholar 

  36. Hermine O, Hoster E, Walewski J, et al. (2010) Alternating courses of 3× CHOP and 3× DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the european mantle cell lymphoma network. Blood Abstract 110

    Google Scholar 

  37. Geisler CH, Kolstad A, Laurell A, et al. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687–93

    Article  PubMed  CAS  Google Scholar 

  38. Gressin R, Caulet-Maugendre S, Deconinck E, et al. (2010) Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 95: 1350–7

    CAS  Google Scholar 

  39. Klui-Nelemans J, Hoster E, Hermine O, et al. (2011) R-CHOP versus R-FC followed by maintenance with rituximab or IFN: first results of a randomized trial for elderly patients with mantle cell lymphoma. Annals of Oncology 22

    Google Scholar 

  40. Martin P, Leonard J (2011) Is there a role for “watch and wait” in patients with mantle cell lymphoma? Semin Hematol 48: 189–93

    Article  PubMed  Google Scholar 

  41. Hess G (2009) Temsirolimus for the treatment of mantle cell lymphoma. Expert Rev Hematol 2: 631–40

    Article  PubMed  CAS  Google Scholar 

  42. Hess G, Herbrecht R, Romaguera J, et al. (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822–9

    Article  PubMed  CAS  Google Scholar 

  43. Goy A, Younes A, McLaughlin P, et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 23: 667–75

    Article  PubMed  CAS  Google Scholar 

  44. O’Connor OA, Wright J, Moskowitz C, et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676–84

    Article  PubMed  Google Scholar 

  45. Fisher RI, Bernstein SH, Kahl BS, et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867–74

    Article  PubMed  Google Scholar 

  46. Le Gouill S, Kroger N, Dhedin N, et al. (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol

    Google Scholar 

  47. Robinson SP, Taghipour G, Canals C, et al. (2006) Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: update from the lymphoma working party of the EBMT. 32nd EBMT Meeting, Hamburg (Allemagne)

    Google Scholar 

  48. Dreyling M, Hoster E, Bea S, et al. (2011) Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma 51: 1612–22

    Article  Google Scholar 

  49. Weniger MA, Wiestner A (2011) Molecular targeted approaches in mantle cell lymphoma. Semin Hematol 48: 214–26

    Article  PubMed  CAS  Google Scholar 

  50. Andersen NS, Pedersen LB, Laurell A, et al. (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27: 4365–70

    Article  PubMed  CAS  Google Scholar 

  51. Ladetto M, Magni M, Pagliano G, et al. (2006) Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 12: 1270–6

    Article  PubMed  CAS  Google Scholar 

  52. Pott C, Hoster E, Delfau-Larue MH, et al. (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115: 3215–23

    Article  PubMed  CAS  Google Scholar 

  53. Pott C, Schrader C, Gesk S, et al. (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107: 2271–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hematologie clinique, CHU de Nantes, Place Alexis Ricordeau, 44093, Nantes cedex 1, France

    S. Le Gouill

  2. Service d’anatomie pathologie du CHU de Nantes, France

    A. Moreau

Authors
  1. S. Le Gouill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Le Gouill .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Le Gouill, S., Moreau, A. (2013). Lymphome à cellules du manteau. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_7

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation